Toripalimab Combination Therapy Without Concurrent Cisplatin for Nasopharyngeal Carcinoma
Yusheng Jie(Sun Yat-sen University), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Xinqiong Huang(Central South University), Xiaozhong Chen(Zhejiang Cancer Hospital), Aihua Lin(Guangzhou University of Chinese Medicine), Shubin Hong(Sun Yat-sen University), Pu‐Yun OuYang(Sun Yat-sen University), Guoxian Long(Tongji Hospital), Yong Su(Henan Provincial People's Hospital), Guangyuan Hu(Tongji Hospital), Meng-Yun Qiang(Zhejiang Cancer Hospital), Feng Jin(China Medical University), Jing Huang(Sun Yat-sen University), Cheng Xu(Sun Yat-sen University), Xu Liu(Sun Yat-sen University), Lei Chen(Zhuzhou Central Hospital), Ning Zhang(First People's Hospital of Foshan), Fei Han(Shenyang Pharmaceutical University), Xiaohui Wang(First Affiliated Hospital Zhejiang University), Ling Li(Tumor Hospital of Guangxi Medical University), Xiaodong Zhu(Fudan University Shanghai Cancer Center), Ying Wang(Wannan Medical College), Rui Guo(Sun Yat-sen University), Weihua Zeng(Zhejiang Cancer Hospital), Hong-Yun Zhao(Sun Yat-sen University), Shaowen Xiao(Jiangxi Provincial Cancer Hospital), Liangfang Shen(Central South University), Desheng Hu(Hubei Cancer Hospital), Yuan Wu(Jiangsu Cancer Hospital), Li‐Ting Liu(Sun Yat-sen University), Li-Xia Lu(Sun Yat-sen University), Luo Huang(First People's Hospital of Foshan), Jingao Li(Jiangxi Provincial Cancer Hospital), Guorong Zou(Panyu District Central Hospital), Wen‐Fei Li(Sun Yat-sen University), Qi Yang(Sun Yat-sen University), Kunyu Yang(Wuhan Union Hospital), Ying Huang(Wuhan University), Wei-Xin Liu(Jiangxi Provincial Cancer Hospital), Yan-Ping Mao(Sun Yat-sen University), Li Lin(Sun Yat-sen University), Ling Guo(Sun Yat-sen University), Yuanyuan Li(Henan Agricultural University), Ling Tang(China University of Petroleum, Beijing), Fang-Yun Xie(Sun Yat-sen University), Guan-Qun Zhou(Sun Yat-sen University), Yan-Qun Xiang(Sun Yat-sen University), Longjiang She(First People's Hospital of Foshan), Xiaoyu Liang(Central South University)
Cited by 26
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
|Journal of Clinical Oncology|2016|1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
SARS-CoV-2 nsp13, nsp14, nsp15 and orf6 function as potent interferon antagonists
|Emerging Microbes & Infections|2020|556